976: Investigating the Role of STAT3 Activation in Canine Osteosarcoma
Grant Status: Closed
Project SummaryThe purpose of this research was to characterize the role of STAT3 in canine osteosarcoma to assess whether this protein represents a novel target for future therapeutic intervention. Dr. London's research team has made significant progress over the 2 year project, defining STAT3 as important for the growth and survival of osteosarcoma cells and identifying small molecule inhibitors capable of blocking STAT3 function. More recently they have been investigating the potential utility of a derivative of the spice curcumin that blocks STAT3. This derivative, FLLL32, was engineered from curcumin by the Medicinal Chemistry group at OSU to be more potent and more specific for targeting of STAT3 than curcumin. Work with this exciting new product is ongoing. Lastly, they have begun to identify factors that may be responsible for the observed activation of STAT3 in osteosarcoma and this will likely provide a broader range of future targets for therapeutic intervention. The overriding goal of this work was to eventually bring STAT3 inhibitors into clinical trials of dogs with osteosarcoma.
Publication(s)Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li P, Kisseberth WK, and London CA, Characterization of STAT3 activation and expression in canine and human osteosarcoma, BMC Cancer, 10:81; 2009.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.